Related Experiment Video

Updated: Jun 15, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

Katri Köninki1, Mark Barok, Minna Tanner

  • 1Institute of Medical Technology, University of Tampere, Biokatu 6, Tampere 33014, Finland.

Cancer Letters
|March 3, 2010
PubMed

Insights

Trastuzumab resistance in breast cancer involves multiple co-existing mechanisms, including PIK3CA mutations and low PTEN, explaining treatment failure. Antibody-dependent cellular cytotoxicity (ADCC) was not correlated with drug sensitivity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Trastuzumab is crucial for HER-2 positive breast cancer treatment.
  • Many patients exhibit intrinsic resistance or develop acquired resistance to trastuzumab therapy.
  • The interplay and coexistence of multiple resistance mechanisms remain incompletely understood.

Purpose of the Study:

  • To investigate co-existing drug resistance mechanisms in trastuzumab-resistant breast cancer cells.
  • To analyze the role of PIK3CA mutations, PTEN, NRG1, and HER-2 expression in trastuzumab and lapatinib resistance.
  • To evaluate the correlation between molecular markers, drug sensitivity, and antibody-dependent cellular cytotoxicity (ADCC).

Main Methods:

  • Analysis of HER-2 positive breast cancer cell lines, including the intrinsically resistant JIMT-1 line.
  • Characterization of phosphatidylinositol 3-kinase (PIK3CA) mutation status, phosphatase and tensin homolog on chromosome 10 (PTEN) and neuregulin-1 (NRG1) mRNA expression.
  • Assessment of HER-2 gene copy number and protein expression, correlated with sensitivity to trastuzumab and lapatinib, and ADCC.

Main Results:

  • JIMT-1 cells exhibited multiple co-existing resistance mechanisms: PIK3CA mutation, low PTEN, high NRG1, and low HER-2 protein expression.
  • While individual resistance factors were present in other cell lines, JIMT-1 uniquely displayed all factors concurrently.
  • Antibody-dependent cellular cytotoxicity (ADCC) was consistently strong across all tested HER-2 positive cell lines, irrespective of molecular markers or drug sensitivity.

Conclusions:

  • Trastuzumab and lapatinib resistance in breast cancer is likely multifactorial, driven by the simultaneous presence of several molecular alterations.
  • Direct drug sensitivity does not correlate with the efficacy of ADCC.
  • Understanding these combined resistance mechanisms is crucial for improving therapeutic strategies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...